Parkinson’s Disease News and Research RSS Feed - Parkinson’s Disease News and Research

New study aims to raise awareness of Parkinson’s disease, improve quality of life

New study aims to raise awareness of Parkinson’s disease, improve quality of life

Raising awareness of Parkinson’s Disease (PD) and improving the quality of life for sufferers is the aim of a new study at Griffith University. [More]
Opioid offers pain relief for Parkinson’s patients

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows. [More]
PD linked to increased cancer risk in Asian population

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations. [More]
Nonmotor features may predict PD progression

Nonmotor features may predict PD progression

The presence of mild cognitive impairment, orthostatic hypotension, and rapid eye movement sleep behaviour disorder may identify a subset of Parkinson’s disease patients with a poor prognosis, research suggests. [More]
Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations. [More]
NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Living Cell Technologies Limited today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. [More]
α-synuclein conformation may underlie neurodegenerative variability

α-synuclein conformation may underlie neurodegenerative variability

Varying structural conformations of α-synuclein may explain how one protein can give rise to distinct forms of neurodegeneration, say researchers. [More]
Promising results for multi-source DBS in Parkinson’s disease

Promising results for multi-source DBS in Parkinson’s disease

Deep-brain stimulation targeting the subthalamic nucleus with a multiple-source constant-current device effectively suppresses motor symptoms in patients with advanced Parkinson’s disease, report researchers. [More]
Severe nonmotor symptom burden common in early Parkinson’s

Severe nonmotor symptom burden common in early Parkinson’s

Almost all patients with early Parkinson’s disease have nonmotor symptoms, with more than a third having a severe burden of symptoms, a study shows. [More]
Resting-state connectivity changes underpinning ICDs identified

Resting-state connectivity changes underpinning ICDs identified

The presence of impulse control disorders is associated with reduced resting-state connectivity between part of the associative striatum and both associative and limbic cortical regions in patients with Parkinson’s disease, a study suggests. [More]
Gender influences nonmotor symptoms in early Parkinson’s

Gender influences nonmotor symptoms in early Parkinson’s

The predominant nonmotor symptoms in patients with Parkinson’s disease vary between men and women, shows an analysis of the Parkinson’s Progression Markers Initiative study. [More]
β-amyloid deposition highly variable in synucleinopathy

β-amyloid deposition highly variable in synucleinopathy

A meta-analysis suggests large variability in the prevalence of β-amyloid deposition in patients with synucleinopathies. [More]
RBD persists in Parkinson’s disease patients

RBD persists in Parkinson’s disease patients

Symptoms of rapid eye movement sleep behaviour disorder (RBD) are unlikely to resolve in patients with Parkinson’s disease, show the findings of a 3-year study. [More]
Olfactory bulb changes fall short as imaging marker for PD

Olfactory bulb changes fall short as imaging marker for PD

Functional and histopathological changes in the olfactory bulb in patients with Parkinson’s disease do not equate to a volume change that is detectable on magnetic resonance imaging, say researchers. [More]
Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Deep-brain stimulation of the subthalamic nucleus may improve motor symptoms in patients with Parkinson’s disease by reducing excessive cortical phase–amplitude coupling, researchers report in Nature Neuroscience. [More]
Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders in patients with Parkinson’s disease are not associated with more marked impairment of cognitive function, researchers report. [More]
Early neuropsychiatric symptoms prevalent in PD

Early neuropsychiatric symptoms prevalent in PD

Neuropsychiatric symptoms, but not cognitive impairment, are common in early untreated patients with Parkinson’s disease, suggest findings from the multicentre Parkinson’s Progression Markers Initiative. [More]
Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels are upregulated in patients with early Parkinson’s disease and are associated with disease progression at 2 years, a study shows. [More]
Deep brain stimulation reduces PD pain severity but does not prevent it

Deep brain stimulation reduces PD pain severity but does not prevent it

Subthalamic nucleus deep brain stimulation has a beneficial effect on pain severity in patients with Parkinson’s disease that persists for up to 8 years, say researchers, but new onset of musculoskeletal pain in many suggests its effects are not enduring. [More]
Discovery opens new drug development avenues for treating multiple diseases

Discovery opens new drug development avenues for treating multiple diseases

Researchers at the University of California, San Diego School of Medicine have discovered a control switch for the unfolded protein response (UPR), a cellular stress relief mechanism drawing major scientific interest because of its role in cancer, diabetes, inflammatory disorders and several neural degenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. [More]
Advertisement
Advertisement